| Literature DB >> 32315618 |
Daniel Leonard1, Wei Huang2, Sudeh Izadmehr3, Caitlin M O'Connor4, Danica D Wiredja5, Zhizhi Wang6, Nilesh Zaware7, Yinghua Chen8, Daniela M Schlatzer5, Janna Kiselar5, Nikhil Vasireddi9, Stefan Schüchner10, Abbey L Perl2, Matthew D Galsky11, Wenqing Xu6, David L Brautigan12, Egon Ogris10, Derek J Taylor13, Goutham Narla14.
Abstract
Impairment of protein phosphatases, including the family of serine/threonine phosphatases designated PP2A, is essential for the pathogenesis of many diseases, including cancer. The ability of PP2A to dephosphorylate hundreds of proteins is regulated by over 40 specificity-determining regulatory "B" subunits that compete for assembly and activation of heterogeneous PP2A heterotrimers. Here, we reveal how a small molecule, DT-061, specifically stabilizes the B56α-PP2A holoenzyme in a fully assembled, active state to dephosphorylate selective substrates, such as its well-known oncogenic target, c-Myc. Our 3.6 Å structure identifies molecular interactions between DT-061 and all three PP2A subunits that prevent dissociation of the active enzyme and highlight inherent mechanisms of PP2A complex assembly. Thus, our findings provide fundamental insights into PP2A complex assembly and regulation, identify a unique interfacial stabilizing mode of action for therapeutic targeting, and aid in the development of phosphatase-based therapeutics tailored against disease specific phospho-protein targets.Entities:
Keywords: B56α; PP2A; SMAP; c-Myc; cancer; cryo-EM; phosphatase; small molecule
Mesh:
Substances:
Year: 2020 PMID: 32315618 PMCID: PMC7243596 DOI: 10.1016/j.cell.2020.03.038
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582